SAN FRANCISCO (MarketWatch) -- Dusa Pharmaceuticals Inc. shares leapt 35% to $3.75 in Thursday morning trade. The Wilmington, Mass.-based company announced that the Food and Drug Administration has ...
Says FDA did not grant orphan status to Levulan therapy Levulan developed for prevention of skin cancer Co plans to close its SOTR clinical program Shares plunge 18 pct Aug 6 (Reuters) - DUSA ...
Oct 22 (Reuters) - Dusa Pharmaceuticals will stop developing its Levulan Photodynamic Therapy to treat moderate to severe acne, after the proposed treatment combination failed to show statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results